 Connection
David Moreno to Aged, 80 and over
This is a "connection" page, showing publications David Moreno has written about Aged, 80 and over.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.206 |
|
|
|
-
Moreno DF, Nadeu F, Brasó-Maristany F, Vaqué S, Paz S, Mañé J, Cardús O, Medina E, Lozano E, Rodríguez-Lobato LG, de Daniel A, Tovar N, Cibeira MT, Bladé J, Rosiñol L, Prat A, Colomer D, Fernández de Larrea C. Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P. Front Immunol. 2025; 16:1604089.
Score: 0.097
-
Rodríguez-Lobato LG, de Daniel A, Pereira A, Fernández de Larrea C, Tovar N, Cibeira MT, Moreno DF, Mateos JM, Llobet N, Carcelero E, Munárriz D, Bladé J, Rosiñol L. Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period. Blood Cancer J. 2025 May 26; 15(1):103.
Score: 0.024
-
Moreno D, Ferrándiz L, Pérez-Bernal AM, Ríos JJ, Carrasco R, Camacho F. [Evaluation of a screening system for patients with pigmented lesions using store-and-forward teleconsultation]. Actas Dermosifiliogr. 2005 May; 96(4):222-30.
Score: 0.024
-
Zugasti I, Tormo-Ratera M, Oliver-Caldés A, Soler-Perromat JC, González-Calle V, Moreno DF, Cabañas V, López-Muñoz N, Bartolomé-Solanas Á, Español-Rego M, Reguera-Ortega JL, Rosiñol L, López-Corral L, Tovar N, Rodríguez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua Á, González-Navarro EA, Martínez-López J, Mateos MV, Tomás X, Setoain X, Fernández de Larrea C. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):571-582.
Score: 0.024
-
Isola I, Brasó-Maristany F, Moreno DF, Mena MP, Oliver-Calders A, Paré L, Rodríguez-Lobato LG, Martin-Antonio B, Cibeira MT, Bladé J, Rosiñol L, Prat A, Lozano E, Fernández de Larrea C. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Front Immunol. 2021; 12:792609.
Score: 0.019
-
Rodríguez-Lobato LG, Pereira A, Fernández de Larrea C, Cibeira MT, Tovar N, Jiménez-Segura R, Moreno DF, Oliver-Caldés A, Rosiñol L, Bladé J. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. Br J Haematol. 2022 02; 196(3):649-659.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|